Travere Therapeutics (TVTX) closed at $49.60 on November 6, 2026, up 1.5% from the previous close, on volume of 951,860 shares (30-day average 2,275,560).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Diagonal Put Spread | 15-Jan-27 : 21-Jan-2850 : 47.5 P | 1,508 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Travere Therapeutics (TVTX) Receives a Buy from J.P. Morgan
TipRanks (Fri, 6-Nov 9:58 AM ET)
Leerink Partners Sticks to Its Buy Rating for Travere Therapeutics (TVTX)
TipRanks (Thu, 5-Nov 9:31 AM ET)
Guggenheim Keeps Their Buy Rating on Travere Therapeutics (TVTX)
TipRanks (Wed, 4-Nov 8:55 AM ET)
TipRanks (Wed, 4-Nov 4:20 AM ET)
TipRanks (Wed, 4-Nov 1:03 AM ET)
Travere Therapeutics to Participate at Upcoming Investor Conferences
Business Wire (Tue, 3-Nov 4:30 PM ET)
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)
TipRanks (Tue, 3-Nov 9:15 AM ET)
TipRanks (Tue, 3-Nov 8:30 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Travere Therapeutics (TVTX)
TipRanks (Tue, 3-Nov 8:10 AM ET)
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo
TipRanks (Tue, 3-Nov 7:56 AM ET)
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics trades on the NASDAQ stock market under the symbol TVTX.
As of November 6, 2026, TVTX stock price climbed to $49.60 with 951,860 million shares trading.
TVTX has a beta of 1.53, meaning it tends to be more sensitive to market movements. TVTX has a correlation of 0.10 to the broad based SPY ETF.
TVTX has a market cap of $4.61 billion. This is considered a Mid Cap stock.
Last quarter Travere Therapeutics reported $225 million in Revenue and -$.31 earnings per share. This beat revenue expectation by $30 million and missed earnings estimates by -$.59.
In the last 3 years, TVTX traded as high as $68.73 and as low as $5.12.
The top ETF exchange traded funds that TVTX belongs to (by Net Assets): VTI, IWM, XBI, VXF, VB.
TVTX has outperformed the market in the last year with a price return of +48.9% while the SPY ETF gained +10.8%. However, in the short term, TVTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -20.6% vs -4.1% return in SPY. But in the last 2 weeks, TVTX shares have fared better than the market returning -1.0% compared to SPY -3.2%.
TVTX support price is $47.07 and resistance is $50.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVTX shares will trade within this expected range on the day.
